Vaccine Exec Named SBRI Chair
Luke Timmerman10/1/09
Todd Patrick, a longtime vaccine company executive, has been named the chairman of the board of trustees at Seattle Biomedical Research Institute. Patrick is the former president of ID Biomedical, the Vancouver, BC and Bothell, WA-based vaccine developer that was acquired by GlaxoSmithKline for $1.5 billion in 2005. Patrick has served on the SBRI board for two years, and takes the chairmanship as the nonprofit research institute prepares to advance a novel malaria vaccine candidate from the lab to its first clinical trial in early 2010.
Luke Timmerman is the National Biotech Editor of Xconomy, and the Editor of Xconomy Seattle. E-mail him at ltimmerman@xconomy.com or follow him on Twitter at twitter.com/ldtimmerman.
